1. Home
  2. LQDA vs NMFC Comparison

LQDA vs NMFC Comparison

Compare LQDA & NMFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • NMFC
  • Stock Information
  • Founded
  • LQDA 2004
  • NMFC 2010
  • Country
  • LQDA United States
  • NMFC United States
  • Employees
  • LQDA N/A
  • NMFC N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • NMFC Finance/Investors Services
  • Sector
  • LQDA Health Care
  • NMFC Finance
  • Exchange
  • LQDA Nasdaq
  • NMFC Nasdaq
  • Market Cap
  • LQDA 1.3B
  • NMFC 1.3B
  • IPO Year
  • LQDA 2018
  • NMFC 2011
  • Fundamental
  • Price
  • LQDA $14.03
  • NMFC $10.99
  • Analyst Decision
  • LQDA Strong Buy
  • NMFC Hold
  • Analyst Count
  • LQDA 7
  • NMFC 2
  • Target Price
  • LQDA $26.67
  • NMFC $11.50
  • AVG Volume (30 Days)
  • LQDA 886.3K
  • NMFC 543.0K
  • Earning Date
  • LQDA 05-12-2025
  • NMFC 04-30-2025
  • Dividend Yield
  • LQDA N/A
  • NMFC 12.06%
  • EPS Growth
  • LQDA N/A
  • NMFC N/A
  • EPS
  • LQDA N/A
  • NMFC 1.03
  • Revenue
  • LQDA $15,610,000.00
  • NMFC $371,666,000.00
  • Revenue This Year
  • LQDA N/A
  • NMFC N/A
  • Revenue Next Year
  • LQDA $208.28
  • NMFC N/A
  • P/E Ratio
  • LQDA N/A
  • NMFC $10.72
  • Revenue Growth
  • LQDA N/A
  • NMFC N/A
  • 52 Week Low
  • LQDA $8.26
  • NMFC $10.62
  • 52 Week High
  • LQDA $16.99
  • NMFC $12.81
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 40.61
  • NMFC 30.42
  • Support Level
  • LQDA $13.50
  • NMFC $10.93
  • Resistance Level
  • LQDA $14.61
  • NMFC $11.46
  • Average True Range (ATR)
  • LQDA 0.71
  • NMFC 0.24
  • MACD
  • LQDA -0.27
  • NMFC -0.08
  • Stochastic Oscillator
  • LQDA 19.70
  • NMFC 5.50

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About NMFC New Mountain Finance Corporation

New Mountain Finance Corp is a closed-end, non-diversified management investment company. It invests in equity interests such as preferred stock, common stock, warrants, or options received in connection with debt investments or may include direct investment in the equity of private companies. The company's investment objective is to generate current income and capital appreciation through sourcing and origination of debt securities at all levels of the capital structure, including first and second-lien debt, notes, bonds, and mezzanine securities.

Share on Social Networks: